We studied the effects of IL4 on the spontaneous proliferation of chronic myelomonocytic leukemia (CMMoL) cells in vitro.
Introduction
IL-4 is a T lymphocyte-derived cytokine with a variety of biologic properties. Originally being described as a cofactor for the proliferation of B cells (1) , this glycoprotein also binds to receptors on hemopoietic stem cells (2) , T lymphocytes, mast cells, and monocytes/macrophages (3), and shows various biological activities. In normal hemopoiesis, IL-4 exerts significant stimulatory effects on multilineage progenitors (colonyforming unit-granulocyte/erythroid/macrophage/megakaryocyte [CFU-GEMM]) (4) , and synergistically supports the growth ofburst-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte/macrophage (CFL-GM) and CFU-GEMM with erythropoietin (Epo), G-CSF or IL-6 (5, 6) . On the other hand, IL-4 is known to inhibit the growth of M-CSF or GM-CSF-dependent human macrophage progenitors (CFU-M) (7) and IL-3-dependent BFU-E (8) . Recently, it has been demonstrated that IL-4 exerts suppressive effects on the factor-dependent leukemic blast colony formation in certain cases of acute myelogenous leukemia (AML)' (9, 10) .
IL4 is also known to act negatively on cytokine synthesis from human monocytes; IL-4 was found to be able to suppress the production of TNF-a, IL-lI-# and IL-6 by lipopolysaccharide-and/or gamma-interferon-stimulated normal human monocytes (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . This suppression was demonstrated to occur at the level of transcription (1 1-13) .
Chronic myelomonocytic leukemia (CMMoL) is a peculiar form of myeloproliferative disorders characterized by the preferential proliferation of monocytes (15, 16) . In contrast to cells from chronic myelogenous leukemia, which rarely form colonies without an exogenous colony-stimulating factor, CMMoL cells possess the capability of spontaneous colony formation in a semisolid medium (17) (18) (19) . Monocytes/macrophages have been shown to produce a variety of cytokines including IL-1, IL-6, G-CSF (20) , GM-CSF (21), M-CSF (22) , and TNF-a. Accordingly, an autocrine growth mechanism supported by monokines released from CMMoL cells in association with monocytoid differentiation is suggested, as has indeed been previously demonstrated in certain cases with acute myelogenous leukemia (23) .
These evidences led us to investigate the possibility of a negative regulatory role ofIL4 in the autocrine growth mechanism of CMMoL cells. In this paper, we demonstrate the negative regulatory effects of IL-4 on the spontaneous growth of CMMoL cells, and present the evidence that IL-4 exerts its inhibitory effect through the suppression of IL-6 and/or GM-CSF production, both of which act as an autocrine growth factor of CMMoL cells in vitro.
Methods
Patients. Patients' profiles are shown in Table I . All of the nine CMMoL patients studied fulfilled the criteria for a diagnosis of CMMoL based on the report ofthe French-American-British cooperative group (15) . None ofthem had any Ph' chromosomes. A proportion ofblast cells exceeding 5% in the peripheral blood or 20% of nucleated cells in the bone marrow was considered to reflect the acute phase ofthe disease (18) . Cases la, 2a, 4,6, 7, and 9had not received any chemotherapy at the time of sampling. In the remaining cases, chemotherapeutic regimens including low dose aclarubicin (24) or low dose cytosine arabinoside (25) had been administered because of uncontrollable leukocytosis, but all of these cases showed stable or increasing white blood cell counts and no evidence of infection at the time of sampling. Neutralizing antibodies. Rabbit polyclonal Ab against various human growth factors were used for neutralization: anti-IL-4 Ab (neutralizing titer [NT], 4 X 106 U/ml); anti-IL-6 Ab (NT, 1 X 104 U/ml); anti-GM-CSF Ab (NT, 1 X 103 U/ml); anti-G-CSF Ab (NT, 1 x 104 U/ml); anti-IL-I -, Ab (NT, 1 X 103 U/ml); and anti-TNF-a Ab (NT, 1 x lO U/ml) were purchased from Genzyme Corp., Cambridge, MA. These antibodies were specified as not showing any cross-reaction with each other. At the concentrations used in this study, none ofthese were toxic to cell proliferation (data not shown). For the inhibition ofcolony formation, antibodies were incorporated into the semisolid culture medium at the time ofplating. For the neutralization ofIL-4 activity, 1 ml of IL-4 (100 U/ml) was preincubated (37°C for 2 h) with 10 ul of anti-IL-4 Ab.
Cytokine assays. 2 X 106/ml of CMMoL cells and normal monocytes were suspended in IMDM containing 10% FCS with or without different concentrations of IL-4, and the culture supernatants were harvested after incubation for 24 h at 37°C with 5% CO2. Patients' plasma was obtained from 10 of 11 cases. These samples were assayed as follows: IL-6 was measured with an ELISA by using a two-step sandwich method. Briefly, a murine MAb specific for human IL-6 was attached to microtiter wells and samples were applied. After a 18-h incubation at 4°C, a biotin-labeled murine anti-human IL-6 MAb, which could bind different epitopes on the IL-6 from that ofprimary anti-IL-6
MAb, was added. After a 1-h incubation at 23°C, a horseradish peroxidase-conjugated streptoavidin reagent was added, and the absorbance was measured with a microplate colorimeter. IL-1-# and GM-CSF were assayed with an ELISA by using a human interleukin-l-# ELISA kit (Otsuka assay; Otsuka Pharmaceutical Co. Ltd., Japan) and a human GM-CSF ELISA kit (Genzyme Corp.), respectively. G-CSF was measured by means of a radioimmunoassay. Briefly, standards and culture supernatants (0.2 ml) were incubated with 0.1 ml of diluted (1:100) rabbit anti-G-CSF Ab (Kirin Beer Co. Ltd., Tokyo) at 4°C for 48 h. 0.1 ml of '251-labeled rhG-CSF (1 x I0O cpm/ml) was added and incubated for 24 h at 4°C. Samples were mixed with 0.1 ml of diluted (1: 100) rabbit serum and 0.1 ml ofdiluted (1:20) anti-rabbit goat antibodies. After 30 min of incubation at room temperature, bound and free G-CSF were separated by centrifugation, and their radioactivity was measured with a gamma counter. TNF-a was measured with a TNF-a RIA kit (Ire-Medgenix, Fleurus, Belgium).
Results
Effect of IL-4 on DNA synthesis of CMMoL cells. 100 U/ml, and the maximum inhibition was -50%. The inhibition could be abolished by the addition of anti-IL-4 Ab.
Effect ofIL-4 on colony formation of CMMoL cells. also suppressed the spontaneous 14-d colony formation of CMMoL cells. The results are shown in Table III . The dose-dependent inhibition was observed in all of the seven patients who showed spontaneous colony formation, and reached a plateau when IL-4 was added at a concentration of 100 U/ml. The maximum inhibition was 50 to 97% of the total colony formation. The appearance of spontaneous CMMoL colonies and IL-4-mediated inhibition ofcolony formation is illustrated in Fig. 1 . This inhibitory action of IL-4 was completely abolished by the addition of anti-IL-4 antibodies to the culture system. Differential countings of colony types in cases 4 and 7 revealed that the IL-4-induced suppression was observed in all types ofcolonies formed: granulocyte colony-forming cells (G-CFC), GM-CFC and M-CFC (Fig. 2) .
Effect of neutralizing antibodies on colony formation of CMMoL cells. To investigate the autocrine mechanism of CMMoL cell growth, we added neutralizing antibodies against various cytokines to the methylucellulose assay system. The addition of anti-IL-6 or anti-GM-CSF antibodies resulted in a significant reduction of spontaneous colony formation in all and in seven of the eight cases examined, respectively (Table  IV) . Furthermore, the addition ofboth anti-IL-6 and anti-GM-CSF Abs resulted in > 80% suppression of colony numbers in all offour cases studied. However, neither anti-G-CSF, anti-ILl-#, anti-M-CSF, nor anti-TNF-a showed a significant effect on the colony formation in any cases examined.
Effect ofIL-4 on cytokine production by CMMoL cells. We then analyzed the effect of IL-4 on the production of monokines by CMMoL cells. The results are shown in Table V . CMMoL cells produced extremely high levels of IL-6 in all of the nine cases examined, compared with those produced by normal monocytes, although the concentrations varied from case to case. IL-4 inhibited this IL-6 production by CMMoL cells in a dose-dependent manner (Fig. 3) , and this inhibition reached a plateau at a concentration of 100 U/ml. A detectable level of GM-CSF was also observed in two cases (cases la and 5). In these two cases, the production of GM-CSF was also completely inhibited with the addition of 100 U/ml of IL-4 (Table V and Fig. 4) .
The spontaneous production ofIL-I -B, G-CSF, and TNF-a was also observed in seven of eight, three of nine and eight of eight cases examined, respectively. Levels of these monokines were almost similar to those produced by normal monocytes, except for G-CSF in cases la and 7, and TNF-a in cases la and 6, in which more than fivefold amplified production compared with normal monocytes was observed. The addition of 100 U/ml of IL-4 also suppressed the production of all of these monokines.
Concentrations ofplasma IL-6 and GM-CSF in CMMoL patients. Elevation of plasma IL-6 was observed in all the samples collected from six cases where the WBC counts were elevated to more than 40 X 109/liter. The results are shown in Fig.  5 . A significant correlation between plasma IL-6 concentration The addition of antibodies against various growth factors revealed that anti-IL-6 and anti-GM-CSF Abs could suppress spontaneous CMMoL colony formation, while neither anti-G-CSF, anti-IL-1-13, nor anti-M-CSF Ab was able to do this. The combination of anti-IL-6 and anti-GM-CSF Abs inhibited > 80% ofthe colony formation. Therefore, in agreement with a recent report by Everson et al. (19) , it is suggested that IL-6 and GM-CSF play an important role as an autocrine growth factor for CMMoL cells.
The measurement of monokines in the 24-h culture supernatant revealed that CMMoL cells produced extremely high Concentration of IL-4 (U/mi) Figure 3 . Dose-dependent relationships between IL-6 levels in supernatants from 24-h cultures of CMMoL cells and IL-4 concentrations added. IL-4 showed the significant inhibition of IL-6 production by CMMoL cells in a dose-dependent manner in all six cases examined. was not demonstrated in culture supernatants: case 6 with anti-GM-CSF Ab alone, and cases S and 9 with a combination of anti-GM-CSF and anti-IL-6 Abs. This discrepancy may be due to the in vitro uptake of GM-CSF by CMMoL cells, and/or to the relative insensitivity ofan ELISA assay for GM-CSF. TNFa, which is known to be a suppressor ofhematopoietic progenitors, is not actively involved in this inhibitory action of IL-4, because TNF-a production by CMMoL cells was also suppressed by the addition of IL-4. IL-6 was demonstrated to synergistically support the growth of primitive hematopietic progenitors including CFU-GM, BFU-E, and CFU-GEMM with IL-3 (26), and to stimulate the formation of CFU-M in the presence of M-CSF (27) . Caracciolo et al. reported that IL-6 was able to enhance the growth of neutrophilic-granulocytic colonies in the presence of GM-CSF, and that IL-6 alone could induce granulocytic differentiation in an AML cell line (28). In addition, in some AML cases, IL-6 and GM-CSF could stimulate proliferation of AML-CFU (29) (30) (31) , and IL-6 was shown to synergize with GM-CSF in the stimulation of AML-CFU (29, 32) . On the basis ofthese observations, IL-6 and GM-CSF would probably take part in the autocrine growth mechanism of CMMoL depending on their growth-stimulating and differentiation-promoting activities.
It is of major concern whether any relationship exists between the spontaneous in vitro proliferation of CMMoL cells and the in vivo biology of the disease. Several reports have demonstrated the expression of IL-1, IL-6, G-CSF, GM-CSF, and TNF by AML cells (33, 34) . IL-6, G-CSF, and GM-CSF can support the growth of AML-CFU, and the additional IL-l or TNF synergistically enhances the factor-dependent AML-CFU growth in some cases (34, 35) . From these observations, it is implied that some of these factors may be actively involved in the autocrine growth of AML cells. However, Baer et al. suggested the possibility that the expression of these cytokines by AML cells may be an artifact of in vitro culture (36) . In addition to high levels ofIL-6 in the culture supernatant of CMMoL cells, we could also detect considerable levels of IL-6 in uncultured CMMoL cell lysates in all the six cases examined (cases la, 2a, 5, 6, 7, and 9) (data not shown). Furthermore, a positive relationship between plasma IL-6 levels and WBC counts was observed in CMMoL cases, whereas detectable levels (> 4 pg/ml) ofIL-6 were not observed in five normal individuals (data not shown). These results indicate that IL-6 plays an important role in the in vivo proliferation ofCMMoL cells. On the other hand, detectable levels of GM-CSF were demonstrated in 24-h culture supernatants from two CMMoL cases (cases la and 5) in which GM-CSF could also be detected in uncultured cell lysates (data not shown); the elevation of plasma GM-CSF levels was observed in both cases. From these results, it is also suggested that GM-CSF may act as an in vivo autocrine growth factor in at least a minority of CMMoL patients.
In conclusion, IL-4 suppresses the spontaneous prolifera- crine growth factor for CMMoL cells. This strongly suggests that IL-4 may play an important role in the negative regulation of normal or leukemic hematopoiesis.
